Latest news with #BGM
Business Wire
6 days ago
- Health
- Business Wire
Ascensia Launches Global Art Competition Exploring the Link Between Diabetes and Anxiety
BASEL, Switzerland--(BUSINESS WIRE)--Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, has launched its fourth annual global art competition in support of World Diabetes Day 2025. This year, the competition is themed around Diabetes and Anxiety, shining a spotlight on the mental health impact of diabetes and capturing the unfiltered reality of living with the condition. An estimated 3 in 4 people living with diabetes have experienced anxiety, depression or another mental health condition as a result of managing their diabetes i. With the number of people affected by diabetes expected to rise to over 850 million by 2050 ii, this year's This is Diabetes. This is Anxiety. campaign aims to raise awareness and deepen understanding through creativity and storytelling. Submissions are now open globally and free to enter at until October 24, 2025, with the winners announced on World Diabetes Day, a global initiative of the International Diabetes Federation (IDF), held each year on November 14. Koichiro Sato, CEO of Ascensia Diabetes Care and Chief Operating Officer and Chief Strategy Officer of Ascensia's parent company PHC Group, commented: 'World Diabetes Day is a key moment for us to support the global diabetes community. For 2025, we want to shed light on the emotional burden that often goes unseen. The theme of 'This is Diabetes. This is Anxiety.' is deeply important, and we hope this competition provides an outlet for expression, connection and better quality of life.' 'Each year we are inspired by the stories shared through art,' he continued. 'We invite artists, supporters, and advocates to help us show the world what anxiety and diabetes truly look like. Every submission adds to a collective story that deserves to be seen and heard.' In addition to showcasing the Top 20 submissions across Ascensia's platforms, the 2025 competition will introduce a free downloadable coloring-in booklet featuring selected artwork. This new initiative is designed to spark creativity, reflection and learning for individuals and families alike. Prizes include donations of €6,000, €3,000 and €1,000 made in the winners' names to a diabetes charity of their choice. A diverse judging panel – including global artists, diabetes advocates, and Ascensia employees – will evaluate submissions based on creativity, emotional impact, connection to the theme, and storytelling. Now in its fourth year, the competition builds on the momentum of previous This is Diabetes campaigns, which have drawn over 500 entries and delivered donations to diabetes charities on four continents. Ascensia Diabetes Care is a PHC Holdings Corporation (TSE: 6523) company. Terms and conditions apply. Notes for Editors About Ascensia Diabetes Care Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives. We are home to the world-renowned CONTOUR ® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense® Continuous Glucose Monitoring Systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity. Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation. Ascensia products are sold in more than 100 countries. Ascensia has around 1,400 employees and operations in 29 countries. For further information, please visit the Ascensia Diabetes Care website at: About PHC Holdings Corporation PHC Holdings Corporation (TSE 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia Holdings Ltd., LSI Medience Corporation, Mediford Corporation, and Wemex. Together, these companies develop, manufacture, sell and service precision technology across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group's consolidated net sales in FY2024 were JPY 361.6 billion with global distribution of products and services in more than 125 countries.
Business Wire
23-06-2025
- Health
- Business Wire
LifePlus Establishes Global Clinical Validation for First-of-Its-Kind Non-Invasive Glucose and Cuffless BP Monitoring Device and Platform
SAN JOSE, Calif.--(BUSINESS WIRE)-- LifePlus, a Silicon Valley startup redefining personal health monitoring, today announced the clinical validation of LifeLeaf ®, the world's first non-invasive and cuffless wearable for continuous glucose and blood pressure tracking. The device, tested in global multi-center trials including Mayo Clinic, AMCR Clinic – San Diego, CA, Cleveland Clinic – Abu Dhabi, and Hospital Sebarang Jaya – Penang, Malaysia, delivers real-time insights without needles, invasive sensors, or cuffs, setting a new standard in scalable, preventive care management. LifeLeaf delivers clinically validated performance without the usual barriers of needles, cuffs, or cost. Share 'LifeLeaf delivers clinically validated performance without the usual barriers of needles, cuffs, or cost,' said Dr. Samuel J. Asirvatham and Dr. Narayan G. Kowlgi of Cardiovascular Medicine, Mayo Clinic, Rochester, MN. 'By making blood pressure and glucose monitoring effortless and non-invasive, it drives better patient adherence, which is crucial for managing chronic conditions like hypertension and diabetes. This scalable solution has a strong potential to transform care models globally by enabling proactive, patient-friendly disease management.' Global Dataset LifePlus has collected and analyzed over 70,000 paired multi-biomarker datapoints from more than 500 human subjects across 14 countries and 4 continents. 'This robust dataset spans a wide range of demographics—including skin tone, age, gender, and BMI—supporting the development of proprietary signal processing and highly generalizable, multi-biomarker advanced AI/ML algorithms and models,' said Ben Mbouombouo, Chief Operating Officer and Product GM of LifePlus. Clinical Results LifePlus has already conducted multiple clinical studies to demonstrate clinical validation for LifeLeaf. The most recent results of its performance vs BGM for glucose monitoring are scheduled to be showcased at the upcoming American Diabetes Association (ADA) Meeting, June 20-23, 2025. Earlier, LifeLeaf's performance vs CGM was shared at the Advanced Technology and Treatment for Diabetes (ATTD) meeting in 2023. LifePlus also published clinical validation results for blood pressure in the European Society of Hypertension meeting in 2023. Please see key highlights below: Glucose Monitoring In head-to-head studies, LifeLeaf achieved an impressive 10.8% MARD against BGM references 1 and 8.5% MARD against Dexcom G6 2 for a target dynamic range of 70-250 mg/dL, demonstrating non-invasive glucose monitoring is not only possible, but viable and scalable for real-world use. LifeLeaf attained a low 2% outlier rate 1 in blinded continuous glucose monitoring studies, comparable with invasive alternatives and underscoring its clinical reliability. Blood Pressure The cuffless blood pressure feature of LifeLeaf demonstrated impressive accuracy, with a mean difference ± standard deviation of –0.02 ± 12.5 mmHg for systolic and 0.03± 8.4 mmHg for diastolic measurements 3 for a supported dynamic range of 90/55-170/110 mmHg, validated across multiple clinical studies and real-world settings. LifeLeaf collected indefinite long-term blood pressure data as opposed to traditional ambulatory monitors, offering continuous, real-world views. LifePlus is engaged with the world's leading clinicians to establish a new longitudinal metric for assessing arterial stiffness that may better predict long-term effects of hypertension and related cardiovascular outcomes. LifeLeaf is unique because it does not require needles, cuffs, or calibration as current solutions do. It is 70% more cost-effective over a 12-month period and supports effortless daily use, which is critical for maintaining a high degree of patient adherence and delivering preventive insights. 'The results presented at ADA this year show that LifeLeaf has the potential to provide accurate data, without invasiveness or complexity,' said Dr. Timothy S. Bailey of Headlands Research – AMCR Clinic, Escondido, CA, and Dr. Jerome S. Fischer of MDRequest, San Antonio, TX. 'This kind of non-invasive monitoring is uniquely poised to improve patient adherence and enable earlier detection – two critical factors in managing chronic conditions.' Upcoming Global Clinical Trials LifePlus is now initiating additional longitudinal outcome studies for LifeLeaf across Asia, Europe, Middle East and North America, focusing on prediabetic and hypertensive populations. The goal: to prove that continuous, passive monitoring can lead to earlier interventions and measurable reductions in chronic disease incidence. 'We're incredibly encouraged by the clinical validation at world-class institutions like Mayo Clinic and Cleveland Clinic,' said Dr. Alodeep Sanyal, co-founder and CEO of LifePlus. 'It confirms what we have believed from the beginning: that non-invasive, AI-powered monitoring can be reliable and scalable. The growing global interest from healthcare providers, partners and investors reaffirms that we are at the forefront of a major shift in how we manage and prevent chronic disease.' With global spending on diabetes and cardiovascular care projected to exceed $1.5 trillion annually by 2030, the market is primed for solutions that go beyond reactive treatment. LifeLeaf is the first clinically validated solution of its kind in this space, targeting a $100B+ total addressable market. To learn more about partnership, pilot opportunities, or investment in LifeLeaf's clinically validated platform, visit Footnotes 1. Improved accuracy of a fully non-invasive continuous glucose monitor in a diverse population. T. Bailey et al. American Diabetes Association (ADA) Annual Meeting 2025. 2. The feasibility of non-invasive continuous glucose monitoring with the novel LifeLeaf wristwatch and platform. T. Bailey et al. Advanced Technology and Treatment in Diabetes (ATTD) Annual Meeting 2023. 3. The feasibility of cuffless, non-occlusive blood pressure assessments using the novel LifeLeaf wristwatch and platform. European Society of Hypertension (ESH) Annual Meeting 2023. About LifePlus LifePlus is committed to transforming how people manage and improve their health. At the heart of our innovation is LifeLeaf ®, the world's first non-invasive, effortless, wrist-worn medical device and platform for continuous, real-time remote patient monitoring. Powered by AI, this technology empowers individuals with real-time insights into their vital health parameters, enabling proactive health management, early intervention, and seamless information sharing with loved ones and care teams. Designed for the billions worldwide at risk of chronic diseases, LifePlus is redefining everyday health monitoring with comfort, continuity, and confidence.
Yahoo
28-05-2025
- Business
- Yahoo
From Virtual Agents to Embodied and Industry-Specific AI: BGM Acquires Xingdao Intelligent and YD Network, Advancing AI on Two Fronts
CHENGDU, China, May 28, 2025 /PRNewswire/ -- BGM Group Ltd. (the "Company" or BGM) (NASDAQ: BGM) today announced that it has entered into definitive transaction agreements with the existing shareholders of Xingdao Intelligent Cloud Chain (Shenzhen) Co., Ltd. ("Xingdao Intelligent") and YD Network Technology Company Limited ("YD Network"). Under the terms of the agreements, BGM will acquire 100% of the equity interests of both companies at a combined valuation of RMB800 million. The consideration will be paid through the issuance of 37,123,142 newly issued Class A ordinary shares of BGM at a price of US$3.0 per share. The transactions are expected to close by the end of June 2025, subject to customary closing conditions. Upon completion, the shareholders of Xingdao Intelligent and YD Network will collectively hold approximately 15.6% of BGM's total outstanding share capital. Xingdao Intelligent is a leading manufacturer and operator of embodied service robots in China. The company has developed proprietary robotic hardware systems and foundational algorithms, positioning itself as a key builder of intelligent workforce systems that integrate embodied robotics, multi-robot product suites, and AI-powered scenario-based services. With over 300 patents related to service robotics, Xingdao Intelligent has a significant presence in areas such as mechanical design, intelligent perception, and autonomous decision-making. The company's products are widely applied in industries including restaurant services, retail malls and supermarkets, building management, hospitals, and industrial inspections. The acquisition will enable BGM to deepen its AI capabilities by integrating hardware and software, completing the "perception-understanding-execution" cycle in real-world applications. YD Network is a pioneering company dedicated to advancing intelligent stock trading through AI. Through its proprietary financial models and quantitative algorithms, the company offers services such as intelligent stock selection, trading strategy optimization, and risk management. Its solutions are used by a range of investors, including individual traders, investment banks, and private equity firms, with a significant successful track record in the U.S. stock and options markets. By acquiring YD Network, BGM will expand its AI capabilities into the fintech sector, building a cross-industry intelligence ecosystem that spans marketing, labor, and capital markets, unlocking new growth avenues. Chen Xin, Chief Executive Officer of BGM, commented, "We believe the future of AI lies in multi-agent collaboration—across both virtual and physical domains, and into deep vertical applications. The acquisitions of Xingdao Intelligent and YD Network represent two major breakthroughs for us: one in embodied intelligence and the other in industry-specific AI applications. This will not only enhance our AI workforce platform but also open up a new frontier in stock and capital markets. These moves not only expand the boundaries of our business, but also lay a solid foundation for the continued evolution of our products and deeper industry integration." BGM is accelerating its "multi-agent AI productivity platform" strategy, building a comprehensive matrix of capabilities that includes AI-powered marketing, AI workforce platforms, AI-driven industry applications, and AI infrastructure. With the addition of Xingdao Intelligent and YD Network, BGM will strengthen its position across hardware-software integration, industry expansion, and algorithmic innovation, enabling the Company to offer more efficient, intelligent, and scalable solutions to clients worldwide. View original content: SOURCE BGM Group Ltd
Hans India
17-05-2025
- Hans India
East Coast Railway AGM interacts with staff
Visakhapatnam: Additional General Manager (AGM) of East Coast Railway Mohes Kumar Behera conducted an inspection at Visakhapatnam on Friday and participated in the Biennial General Body Meeting (BGM) of the All India Guards Council (AIGC) held at the Railway Institute. During the visit, Mohes Kumar Behera interacted with staff, train managers (Guards), and officers. Speaking on the occasion, he emphasised the paramount importance of safety, security, and enhanced passenger amenities. He urged the staff and officers to work diligently towards reducing passenger complaints by addressing issues efficiently. While interacting with the Train Managers, the AGM highlighted their critical roles and responsibilities, and encouraged open discussion regarding their grievances, suggestions. Addressing the officers, the AGM advocated for the implementation of good governance and robust administrative practices. He stressed the need to focus on cleanliness, freight loading, safe train operations, and track maintenance. Further, MK Behera also advised officers to prioritise infrastructural development to meet the targets set by the railway board. He called for the preparation of comprehensive action plans to overcome challenges through effective planning and teamwork. He was accompanied by Divisional Railway Manager Lalit Bohra, ADRMs Manoj Kumar Sahoo and E Santharam.
The Hindu
16-05-2025
- General
- The Hindu
East Coast Railway Additional General Manager stresses on the importance of safety, security and enhanced passenger amenities
Mohes Kumar Behera, Additional General Manager (AGM) of East Coast Railway, conducted an inspection and participated in the Biennial General Body Meeting (BGM) of the All India Guards Council (AIGC) held at the Railway Institute here on Friday. He was accompanied by Lalit Bohra, Divisional Railway Manager. During his visit, Mr. Behera interacted with the staff, Train Managers (Guards) and officers. He emphasised the importance of safety, security and enhanced passenger amenities. He urged all the staff and officers to work diligently towards reducing passenger complaints by addressing issues promptly and efficiently. While interacting with the Train Managers, the AGM highlighted their critical roles and responsibilities, and encouraged open discussion regarding their grievances, suggestions, and any support required from the administration. He assured them of the administration's commitment to providing a conducive work environment. In his meeting with officers, the AGM advocated the implementation of good governance and robust administrative practices. He stressed the need to focus on cleanliness, freight loading, safe train operations, and track maintenance. He also advised officers to prioritise infrastructural development to meet the targets set by the Railway Board. He called for the preparation of comprehensive action plans to overcome challenges through effective planning and teamwork. ADRM Operations Manoj Kumar Sahoo, ADRM Infra E. Santharam and branch officers of various departments were present in the meeting held at the DRM office.
